You are here: Home » Current Affairs » Coronavirus » News
Covid-19 impact: Centre gives 5-month extension to renewable projects
Business Standard

Covid-19: At Rs 2,800 per dose, Zydus launches cheapest remdesivir brand

Zydus plans to supply large quantities of the injectable drug in the market soon

Topics
Coronavirus Vaccine | Cadila Healthcare  | Coronavirus

Sohini Das & Vinay Umarji  |  Mumbai | Ahmedabad 



remdesivir, coronavirus, drugs, covid, pharma
Remdesivir and other expensive Covid drugs like Roche's tocilizumab (which is marketed here by Cipla) have been selling in the black market

Disrupting the Covid drug market in the country, (Zydus Cadila) on Thursday launched the cheapest remdesivir brand Remdac, priced at Rs2,800 per dose. The drug is 30 per cent cheaper than Cipla’s Cipremi, which was the cheapest remdesivir in the market till now.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Thu, August 13 2020. 19:34 IST

RECOMMENDED FOR YOU